We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Whole Genome Test Pinpoints Mutations in Neonates

By LabMedica International staff writers
Posted on 15 Oct 2012
A prototype whole genome sequencing test on blood sample that only takes 50 hours has been developed for neonatal intensive care units (NICU) enabling doctors to diagnose genetic diseases. More...


There are at least 3,500 known genetic diseases caused by mutations in DNA, and treatments are available for more than 500 of them but currently it takes about a month to get the sort of results that allow pediatricians to make a definitive diagnosis.

Scientists at the Children's Mercy Hospital (Kansas City, MO, USA) used a whole genome sequencing (WGS) program they developed themselves called STAT-Seq, in conjunction with a sequencing machine, to cast a broad net over the 3,500 or so known genetic diseases and achieve results in time for doctors to make clinical decisions.

The prototype was tested by doing retrospective 50-hour WGS on two children whose molecular diagnoses had already been done the conventional way. Then the scientists did tests on children not tested before, and confirmed the results by sequencing genomes of parents and siblings. These tests revealed, in one newborn a severe Gap junction beta-2 protein (GJB2)-related skin disease. In another they uncovered Breast Cancer (BRCA1)-associated ataxia telangiectasia mutated (ATM) activator 1(BRAT1)-related lethal neonatal rigidity and multifocal seizure syndrome. They also found other gene defects in additional children, including a new disease-causing mutation, B-cell lymphoma 9-like protein (BCL9L).

The investigators have cut down the time by developing statistical software that matches up doctors' unique descriptions of the patient's condition and symptoms, against a comprehensive set of relevant diseases while looking at the genome test results. By allowing the individual features to be entered, the software substantially automates identification of the DNA variations that can explain the child's condition. The program they developed themselves, the STAT-Seq, was used in conjunction with a HiSeq 2500 sequencing machine (Illumina Inc., San Diego, CA, USA).

The authors concluded that rapid WGS can potentially broaden and foreshorten differential diagnosis, resulting in fewer empirical treatments and faster progression to genetic and prognostic counseling. By shortening the time-to-diagnosis, they may markedly reduce the number of other tests performed and reduce delays to a diagnosis, as reaching an accurate diagnosis quickly can help to shorten hospitalization and reduce costs and stress for families. The study was published on October 3, 2012, in the journal Science Translational Medicine.

Related Links:

Children's Mercy Hospital
Illumina Inc.



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.